Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats

European Neuropsychopharmacology

Volumn 20, Issue 3, 2010, Pages 187-194

  Choi, Yong Kee ^a,b   Moran Gates, Taylor ^a   Gardner, Matthew P ^a   Tarazi, Frank I ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Autoradiography; Caudate putamen; Childhood onset schizophrenia; Frontal cortex; Risperidone; Serotonin receptors

Indexed keywords

RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR;

AGE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN DEVELOPMENT; BRAIN REGION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG REEXPOSURE; FOREBRAIN; FRONTAL CORTEX; HIPPOCAMPUS; JUVENILE ANIMAL; LOW DRUG DOSE; MALE; MORNING DOSAGE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; RECEPTOR UPREGULATION; SEROTONIN BRAIN LEVEL; SEROTONINERGIC SYSTEM; SINGLE DRUG DOSE;

AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; RISPERIDONE;

EID: 75149195759     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.09.002     Document Type: Article

References (56)

1. Alaghband-Rad J., McKenna K., Gordon C.T., Albus K.E., Hamburger S.D., Rumsey J.M., Frazier J.A., Lenane M.C., and Rapoport J.L. Childhood-onset schizophrenia: the severity of premorbid course. J. Am. Acad. Child Adolesc. Psych. 34 (1995) 1273-1283
2. Armenteros J.L., Whitaker A.H., Welikson M., Stedge D.J., and Gorman J. Risperidone in adolescents with schizophrenia: an open pilot study. J. Am. Acad. Child Adolesc. Psych. 36 (1997) 694-700
3. Arnt J., and Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18 (1998) 63-101
4. Baldessarini R.J., and Tarazi F.I. Pharmacotherapy of psychosis and mania. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics (2005), McGraw-Hill, New York 461-500
5. Barnard L., Young A.H., Pearson J., Geddes J., and O'Brien G. A systematic review of the use of atypical antipsychotics in autism. J. Psychopharmacol. 16 (2002) 93-101
6. Bar-Peled O., Gross-Isseroff R., Ben-Hur H., Hoskins I., Groner Y., and Biegon A. Fetal human brain exhibits a prenatal peak in the density of serotonin 5-HT1A receptors. Neurosci. Lett. 127 (1991) 173-176
7. Beitchman J.H. Childhood schizophrenia. A review and comparison with adult-onset schizophrenia. Psychiatr. Clin. North Am. 8 (1985) 793-814
8. Bruggeman R., van der Linden C., Buitelaar J.K., Gericke G.S., Hawkridge S.M., and Temlett J.A. Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J. Clin. Psychiatry 62 (2001) 50-56
9. 2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 15 (1996) 442-455
10. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., and Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14 (1996) 87-96
11. Choi Y.K., Gardner M.P., and Tarazi F.I. Effects of risperidone on glutamate receptor subtypes in developing rat brain. Eur. Neuropsychopharmacol. 19 (2009) 77-84
12. 1A receptor binding sites in some areas of the rat CNS during postnatal development. Int. J. Dev. Neurosci. 5 (1987) 171-180
13. Erickson C.A., Stigler K.A., Posey D.J., and McDougle C.J. Risperidone in pervasive developmental disorders. Expert Rev. Neurother. 5 (2005) 713-719
14. Findling R.L., and McNamara N.K. Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J. Clin. Psychiatry 65 Suppl 6 (2004) 30-44
15. Florijn W.J., Tarazi F.I., and Creese I. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. J. Pharmacol. Exp. Ther. 280 (1997) 561-569
16. Francis P.T., Pangalos M.N., Pearson R.C.A., Middlemiss D.N., Stratmann G.C., and Bowen D.M. 5-Hydroxytryptamine-1A but not 5-hydroxytryptamine-2 receptors are enriched on neocortical pyramidal neurons destroyed by intrastriatal volkensin. J. Pharmacol. Exp. Ther. 261 (1992) 1273-1281
17. Frazier J.A., Cohen L.G., Jacobsen L., Grothe D., Flood J., Baldessarini R.J., Piscitelli S., Kim G.S., and Rapoport J.L. Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. J. Clin. Psychopharmacol. 23 (2003) 87-91
18. Gilman A.G. G proteins: transducers of receptor-generated signals. Ann. Rev. Biochem. 56 (1987) 615-649
19. Gordon C.T., Frazier J.A., McKenna K., Giedd J., Zametkin A., Zahn T., Hommer D., Hong W., Kaysen D., and Albus K.E. Childhood-onset schizophrenia: an NIMH study in progress. Schizophr. Bull. 20 (1994) 697-712
20. 2A receptors by agonists and antagonists. Brain. Res. Bull. 56 (2001) 441-451
21. Grcevich S.J., Findling R.L., Rowane W.A., Friedman L., and Schulz S.C. Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. J. Child Adolesc. Psychopharmacol. 6 (1996) 251-257
22. Green W.H., Padron-Gayol M., Hardesty A.S., and Bassiri M. Schizophrenia with childhood onset: a phenomenological study of 38 cases. J. Am. Acad. Child Adolesc. Psych. 31 (1992) 968-976
23. Greene W.H. Econometric Analysis. fourth ed. (2000), Prentice Hall, Upper Saddle River, NJ 462-465
24. Grothe D.R., Calis K.A., Jacobsen L., Kumra S., DeVane C.L., Rapoport J.L., Bergstrom R.F., and Kurtz D.L. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. J. Clin. Psychopharmacol. 20 (2000) 220-225
25. 2 receptor binding in patients with chronic schizophrenia. Psychopharmacology 112 (1993) S35-S39
26. 2A receptor antagonist M100, 907 attenuates motor and 'impulsive-type' behaviors produced by NMDA receptor antagonism. Psychopharmacology 170 (2003) 309-319
27. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76 (2001) 1521-1531
28. Jacobsen L.K., and Rapoport J.L. Childhood-onset schizophrenia: implications of clinical and neurobiological research. J. Child Psychol. Psychiatry 39 (1998) 101-113
29. Kapur S., VanderSpek S.C., Brownlee B.A., and Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 305 (2003) 625-631
30. 3 dopamine receptors. Cell. Mol. Neurobiol. 14 (1994) 185-191
31. 2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs. Neuropsychopharmacology 13 (1995) 139-150
32. 2A receptors in the rat brain. J. Neural Transm. 107 (2000) 295-302
33. 2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol. Pharmacol. 21 (1982) 301-314
34. McConville B.J., and Sorter M.T. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J. Clin. Psychiatry 65 (2004) S20-S29
35. McCracken J.T., McGough J., Shah B., Cronin P., Hong D., Aman M.G., Arnold L.E., Lindsay R., Nash P., Hollway J., McDougle C.J., Posey D., Swiezy N., Kohn A., Scahill L., Martin A., Koenig K., Volkmar F., Carroll D., Lancor A., Tierney E., Ghuman J., Gonzalez N.M., Grados M., Vitiello B., Ritz L., Davies M., Robinson J., McMahon D., and Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N. Engl. J. Med. 347 (2002) 314-321
36. 1A receptors. J. Pharmacol. Exp. Ther. 295 (2000) 853-861
37. Moran-Gates T., Grady C., Park Y.S., Baldessarini R.J., and Tarazi F.I. Effects of risperidone on dopamine receptor subtypes in developing rat brain. Eur. Neuropsychopharmacol. 17 (2007) 448-455
38. Nicolson R., and Rapoport J.L. Childhood-onset schizophrenia: rare but worth studying. Biol. Psychiatry 46 (1999) 1418-1428
39. Nicolson R., Giedd J.N., Lenane M., Hamburger S., Singaracharlu S., Bedwell J., Fernandez T., Thaker G.K., Malaspina D., and Rapoport J.L. Clinical and neurobiological correlates of cytogenetic abnormalities in childhood-onset schizophrenia. Am. J. Psychiatry 156 (1999) 1575-1579
40. O'Dell S.J., La Hoste G.J., Widmark C.B., Shapiro R.M., Potkin S.G., and Marshall J.F. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 6 (1990) 146-153
41. Paxinos F., and Watson C. The Rat Brain in Stereotaxic Coordinates (1982), Academic Press, New York
42. Pazos A., and Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in rat brain. I. Serotonin-1 receptors. Brain Res. 346 (1985) 205-230
43. Perry R., Pataki C., Munoz-Silva D.M., Armenteros J., and Silva R.R. Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J. Child Adolesc. Psychopharmacol. 7 (1997) 167-179
44. 1A receptor in the rat brain-correlation with receptor binding. J. Neurosci. 12 (1992) 440-453
45. Russell A.T., Bott L., and Sammons C. The phenomenology of schizophrenia occurring in childhood. J. Am. Acad. Child Adolesc. Psych. 28 (1989) 399-407
46. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.M.L., Gompel P.V., Lesage A.S., De Loore K., and Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124 (1996) 57-73
47. 1A receptors in ventral prefrontal cortex in schizophrenia. Biol. Psychiatry 39 (1996) 919-928
48. Spencer E.K., and Campbell M. Children with schizophrenia: diagnosis, phenomenology, and pharmacotherapy. Schizophr. Bull. 20 (1994) 713-725
49. 1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res. 708 (1996) 209-214
50. Tarazi F.I., Zhang K., and Baldessarini R.J. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology 161 (2002) 263-270
51. Tarsy D., Baldessarini R.J., and Tarazi F.I. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16 (2002) 23-45
52. Taylor E.W., Nikam S.S., Lambert G., Martin A.R., and Nelson D.L. Molecular determinants for recognition of RU 24969 analogs at central 5-hydroxytryptamine recognition sites: use of a bilinear function and substituent volumes to describe steric fit. Mol. Pharmacol. 34 (1988) 42-53
53. 3H]ketanserin labeling of 5-hydroxytryptamine2 (5-HT2) receptors in mammalian cells transfected with a rat 5-HT2 cDNA: evidence for multiple states and not multiple 5-HT2 receptor subtypes. Mol. Pharmacol. 38 (1990) 594-598
54. Waddington J.L., and Casey D. Comparative pharmacology of classical and novel (second-generation) antipsychotics. In: Waddington J.L., and Buckley P.F. (Eds). Schizophrenia and Mood Disorders (2000), Butterworth-Heinemann, Oxford 1-13
55. Winer B.J., Brown D.R., and Michels K.M. Statistical Principles in Experimental Design. third ed. (1991), McGraw-Hill, New York 165-166
56. Wright D.E., Seroogy K.B., Lundgren K.H., Davis B.M., and Jennes L. Comparative localization of serotonin1A, 1C, and 2 receptor subtype mRNAs in rat brain. J. Comp. Neurol. 351 (1995) 357-373